<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034484</url>
  </required_header>
  <id_info>
    <org_study_id>AIS-D01</org_study_id>
    <nct_id>NCT05034484</nct_id>
  </id_info>
  <brief_title>A Study of ALPN-303 in Adult Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303 in Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpine Immune Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpine Immune Sciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the&#xD;
      blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug&#xD;
      effects the immune system) of a single dose of an investigational drug called ALPN-303.&#xD;
      Multiple dose levels will be tested.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Type, incidence, and severity of adverse events as assessed by CTCAE</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ALPN-303 Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Regimen A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALPN-303 Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Regimen B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPN-303</intervention_name>
    <description>Multiple dose levels will be evaluated.</description>
    <arm_group_label>ALPN-303 Regimen A</arm_group_label>
    <arm_group_label>ALPN-303 Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching ALPN-303 will be administered</description>
    <arm_group_label>Placebo Regimen A</arm_group_label>
    <arm_group_label>Placebo Regimen B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Summary of Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
          -  Body mass index 18 to 32 kg/m2&#xD;
&#xD;
          -  Agree to avoid strenuous physical activity for 2 days prior to each study visit&#xD;
&#xD;
          -  Agree to use highly effective contraception during the study (all participants) and&#xD;
             for 90 days after study drug dosing (males) or for 60 days after study drug dosing&#xD;
             (females)&#xD;
&#xD;
          -  Male participants must refrain from donating sperm during the study and for 90 days&#xD;
             after study drug dosing&#xD;
&#xD;
          -  Female participants must not be pregnant or breastfeeding and must refrain from&#xD;
             donating ova during the study and for 60 days after study drug dosing&#xD;
&#xD;
        Summary of Exclusion Criteria:&#xD;
&#xD;
          -  Any current disease, condition, or treatment that could interfere with the study,&#xD;
             interfere with interpretation of the data, or pose an unacceptable risk to the&#xD;
             participant&#xD;
&#xD;
          -  History or symptoms of significant psychiatric disease; mild, resolved depression or&#xD;
             anxiety is acceptable&#xD;
&#xD;
          -  History of immunological disorders, auto-immune disorders, acquired or congenital&#xD;
             immune deficiency; see protocol for clarifications/exceptions&#xD;
&#xD;
          -  History of significant hepatic or renal disease or impairment&#xD;
&#xD;
          -  Evidence of an active or suspected cancer or a history of malignancy within the&#xD;
             previous 3 years; see protocol for exceptions&#xD;
&#xD;
          -  History of major organ transplantation with an existing functional graft&#xD;
&#xD;
          -  Use or receipt of prescription medications, over-the-counter medications, herbal&#xD;
             remedies, or investigation products (study drugs) within protocol-defined timeframes&#xD;
             prior to study entry; hormone replacement therapy initiated at least 2 months prior to&#xD;
             screening is acceptable&#xD;
&#xD;
          -  Significant loss of blood (including donation) over 500 mL or transfusion of any blood&#xD;
             product during Screening or within 3 months of Screening&#xD;
&#xD;
          -  Unwilling to refrain from alcohol use â‰¥ 48 hours prior to Study Day -1.&#xD;
&#xD;
          -  Known hypersensitivity, allergy, or intolerance to ALPN-303, Fc-based biologic&#xD;
             therapy, or any of the excipients contained in the ALPN-303 formulation&#xD;
&#xD;
          -  Immunization with any live vaccine within 6 weeks prior to study drug administration,&#xD;
             or expected to require any live vaccines during the study or within 6 weeks after&#xD;
             receiving study drug&#xD;
&#xD;
          -  Acceptable laboratory assessments at Screening and Day -1&#xD;
&#xD;
          -  Positive screen for drugs of abuse or alcohol at Screening or Day -1&#xD;
&#xD;
          -  Positive tests for infectious disease (HIV, hepatitis B, hepatitis C, SARS-CoV-2)&#xD;
&#xD;
          -  Acute infection during or within 6 weeks prior to Screening&#xD;
&#xD;
          -  History of frequent or atypical infections as defined per protocol; signs or symptoms&#xD;
             of immunodeficiency&#xD;
&#xD;
          -  History or presence of any chronic infectious condition&#xD;
&#xD;
          -  Cardiac risk factors, as defined per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles Czank</last_name>
    <phone>61 431 989 342</phone>
    <email>cczank@georgeclinical.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <keyword>BAFF</keyword>
  <keyword>APRIL</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

